Hepatitis B Reactivation Prompts New Warnings for Arzerra, Rituxan Monthly Prescribing Reference The FDA has approved changes to the prescribing information for Arzerra (ofatumumab; GlaxoSmithKline) and Rituxan (rituximab; Genentech) to add a new warning about the risk of hepatitis B virus (HBV) infection reactivation. RELATED: Oncology Resource ... |
